<DOC>
	<DOCNO>NCT00745212</DOCNO>
	<brief_summary>The venous thromboembolism one first cause maternal mortality . Until 2003 , recommendation available optimal use antithrombotic therapy preventive measure thromboembolism pregnant woman . In study , propose : 1 . To gather expert take part French consensus conference local expert create score accordance national international consensus give precise therapeutic strategy . 2 . To evaluate discriminant , feasible useful character new score random prospective multicentric study include 2280 pregnant woman risk thromboembolism placental vascular pathology benefit therapeutic strategy define new score .</brief_summary>
	<brief_title>Evaluation Antithrombotic Therapeutic Strategy Pregnant Women</brief_title>
	<detailed_description>Purpose : To create score inspired first experience i.e . simple , standardize quickly usable day-to-day practice individualize antithrombotics prescription woman risk .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<criteria>multiparous primiparous parturients follow one participating center Presenting least one risk factor venous thromboembolic pathology and/or placental vascular pathology parturient ca n't follow unknown familial personal previous history Parturient contraindication use treatment recommend therapeutic strategy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>venous thromboembolism disease</keyword>
	<keyword>placental vascular pathology</keyword>
	<keyword>antithrombotic treatment</keyword>
	<keyword>symptomatic thromboembolic event</keyword>
	<keyword>pregnant woman</keyword>
	<keyword>score</keyword>
	<keyword>therapeutic strategy</keyword>
	<keyword>heparin</keyword>
	<keyword>aspirin</keyword>
	<keyword>pregnancy pathology</keyword>
</DOC>